Skip to main navigation Skip to search Skip to main content

Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice

  • Edgardo Falcon
  • , Kaitlyn Maier
  • , Shivon A. Robinson
  • , Tiffany E. Hill-Smith
  • , Irwin Lucki*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

Rationale: Buprenorphine (BPN) has been shown to rapidly improve mood in treatment-resistant depressed patients in small clinical studies. However, BPN's effects in preclinical tests for mood and antidepressant efficacy are largely unexplored. Objective: The current study examined the effects of BPN in the forced swim test (FST) and novelty-induced hypophagia (NIH) test as measures of antidepressant and anxiolytic-like effects in C57BL/6 J mice. Microdialysis was used to measure whether BPN engaged kappa-opioid receptor (KORs) in the nucleus accumbens shell (NAcSh) at a behaviorally active dose (0.25 mg/kg). Methods: BPN was tested in the FST at both 30 min and 24 h post-administration. Also measured in the FST at 24 h post-administration were the KOR antagonist norbinaltorphimine (nor-BNI), the MOR agonist morphine and the reference antidepressant desipramine. The anxiolytic effects of BPN were examined in the NIH test 24 h after treatment. The effects of acute injection of BPN and the KOR agonist U50,488 were measured on extracellular dopamine (DA) levels in the NAcSh. Results: BPN produced significant reductions in FST immobility without changing locomotor activity and reduced approach latencies in the novel environment of the NIH test when tested 24 h after treatment. Repeated daily BPN injections for 6 days did not produce tolerance to these behavioral effects. nor-BNI produced a similar antidepressant-like response in the FST 24 h post-injection but morphine and desipramine were ineffective. BPN (0.25 mg/kg) did not alter DA levels when given alone but prevented the KOR agonist U50,488 from reducing DA levels. Conclusions: Acute and subchronic treatment with BPN produced antidepressant and anxiolytic-like responses in mice at doses that engage KORs. These studies support the clinical evidence that BPN may be a novel rapid-acting antidepressant medication and provides rodent models for investigating associated neurochemical mechanisms.

Original languageEnglish
Pages (from-to)907-915
Number of pages9
JournalPsychopharmacology
Volume232
Issue number5
DOIs
StatePublished - Jan 2015

Keywords

  • Antidepressant
  • Anxiety
  • Buprenorphine
  • Depression
  • Dopamine
  • Kappa-opioid receptor
  • Microdialysis

Fingerprint

Dive into the research topics of 'Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice'. Together they form a unique fingerprint.

Cite this